Top View
- GSK and Genmab Announce Submission to US Regulatory Authorities for Arzerra® (Ofatumumab) As 1 St Line Treatment of Chronic Lymphocytic Leukemia (CLL)
- 42 Section 28A August 200814 Uk
- Future Prospects for Medicon Valley
- Genmab and Blink Biomedical Enter Into Commercial License Agreement
- Prospectus Regarding Admittance to Trading and Official
- Holdings As of June 30, 2021
- 20080626 Trading Notice Functional 0076
- Biotech in Denmark 2008 Growing Stronger Biotech in Denmark 2008 Growing Stronger
- Genmab Announces Financial Results for the First Nine Months of 2019
- Financial Highlights
- Georgeson's 2017 Proxy Season Review
- Innovating Antibodies, Improving Lives
- Vanguard Developed Markets Index Fund Annual Report December 31, 2020
- Udsendelsesdag: Anbefaling: Markedskurs: Kursmål: Analytiker
- Hedge Funds Aggressively Short Danish Stocks
- Genmab Announces Preclinical Data to Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
- Genmab Announces Financial Results for the First Half of 2020
- Innovating Antibodies, Improving Lives
- Stoxx® Europe 600 Index
- Fact Sheet As of 06/30/2021
- Portfolio of Investments
- Report Pursuant to Section 28A of the Danish Securities Trading Act
- Remuneration in Danish Large-Cap Companies Benchmarking Executive Management and Board Remuneration
- 1 1 RISK FACTORS an Investment in Genmab's Shares, Including Any New Shares, Involves a High Degree of Risk. in Addition to Th
- Genmab Announces Financial Results for the First Half of 2021
- Semi-Annual Review of the Omx Copenhagen 20 Cap Index
- 2021 Quarterly Report (Unaudited)
- Genmab in Research Cooperation with the Dahanca-Group
- Genmab Announces Completion of Agreement to Transfer Remaining Ofatumumab Rights
- Citi Pure Low Risk Europe Long Short TR Index (CIISLRET)
- Annual Report 2014 1
- Mainstay Epoch Capital Growth Fund Q1 Holdings
- Global Strategy Paper Womenomics Europe Moving Ahead
- Genmab Announces Duobody Platform Collaboration with Lilly
- Portfolio of Investments
- REPORT PURSUANT to SECTION 28A of the DANISH SECURITIES TRADING ACT
- Georgeson's 2016 Proxy Season Review
- Genmab Announces Financial Results for the First Quarter of 2021
- Remuneration in Danish Large-Cap Companies Benchmarking Executive Management and Board Remuneration
- Printmgr File
- 61 Section 28A 151214 Uk
- AVA OMX C25 TRACKER Tracker Certificate Linked to the OMX Copenhagen 25 Index - Issued by Alphabeta Access Products Ltd
- Annual Report
- MSCI Denmark Index (USD) (GROSS)
- AQR International Equity Mutual Fund June 30, 2021
- Genomics in Denmark
- Innovating Antibodies, Improving Lives Key Figures and Highlights · the Company and Products · Other Company Information · Financial Statements · Statements
- State of Medicon Valley 2017
- Innovating Antibodies, Improving Lives
- Globalization and E-Commerce: Growth and Impacts in Denmark
- GENMAB A/S (A Public Company Incorporated with Limited Liability Under the Laws of Denmark, Registered Number 21023884)
- Report Pursuant to Section 28A of the Danish Securities Trading Act
- Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
- June 30, 2021
- State Street Spectrum Unit Trust State Street Spectrum Unit Trust Annual Report and Audited Financial Statements for the Year Ended 30 September 2020
- Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
- Genmab Achieves $3 Million Milestone in Duobody Platform Collaboration with Janssen
- Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, Hexabody®-CD38
- Pax Ellevate Global Women's Leadership Fund USD 7/31/2021 Port
- Proposal for Election of Two New Members of the Board of Directors